Albemarle expands South Haven API production site

Albemarle Corporation, a global developer, manufacturer and marketer of highly engineered specialty chemicals, announced today that its FDA-registered South Haven, Michigan site has expanded and upgraded its multi-product cGMPactive pharmaceutical ingredient (API) manufacturing facility.

Production using the new expanded capacity commenced on June 1, 2012.

This expansion is the latest in a series of projects at the South Haven site to increase capabilities and production throughput, meeting the increasing demand for both generic API products and custom manufacturing service portfolios. In the past two years, the number of custom API projects has more than doubled at the South Haven site. The investment matches the solids handling equipment with the reactor capacity and will enable the company to advance its growing portfolio of custom API products, several of which have progressed to late stage clinical development and pre-registration status.

Albemarle Fine Chemistry Services specializes in enabling its customers to go to market in an efficient and fully compliant manner by providing comprehensive process development and validation capabilities followed by seamless transition into commercial-scale production. Albemarle uses the Quality by Design (QbD) approach to establish manufacturing processes and then speed validated commercial products to market.
Companies in this article
More in Home